(IN BRIEF) Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a hub that will drive breakthroughs in Cardiovascular, Renal, and Metabolism research while also leveraging data science and AI … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI, Alan Garber, Allston, Boston, cardiovascular, data science, drug discovery, Genentech, Harvard Enterprise Research Campus, Healthcare Innovation, Manu Chakravarthy, Maura Healey, METABOLISM, Michelle Wu, Mixed-Use Campus, partnership, Public Private Partnership, Renal, research and development, Roche, Roche Genentech Innovation Center Boston, Thomas Schinecker, USD11 Billion Investment
(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
(IN BRIEF) UBS Group AG has nominated Renata Jungo Brüngger and Lila Tretikov for election to its Board of Directors at the Annual General Meeting on 10 April 2025. Jungo Brüngger brings expertise in governance, sustainability, and legal affairs from … Read the full press release
Posted in Banks, Business, Financial, Industrial, Investment, Management, News, Switzerland
Tagged Annual General Meeting, appointment, artificial intelligence, Audit Committee, Board of Directors, Claudia Böckstiegel, Colm Kelleher, Daimler Truck Holding AG, ENGIE, Governance, Governance and Nominating Committee, leadership, Lila Tretikov, Mercedes-Benz Group AG, Microsoft, Munich Re, Nathalie Rachou, New Enterprise Associates, Renata Jungo Brüngger, Risk Committee, Roche, sustainability, technology-driven business transformation, UBS
(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release
Posted in France, Healthcare, Marketing, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged Alfred Samuels, AstraZeneca, Azafaros, Beyza Klein, Biotech, Biotechnology Conference, Boehringer Ingelheim, Bre Bugbee-Barrett, Catherine Coulouvrat MD, Chiesi Farmaceutici SpA, clinical development, clinical operations, clinical research, clinical research enterprise, clinical trial, clinical trials, Conference Forum, decentralized clinical trials, Gisela Linthorst, GSK, Harry Verbunt, HTA/Regulatory requirements, Johnson & Johnson Innovative Medicine, Lea-Isabelle Proulx PhD, life post-cancer diagnosis, Marisa Minetti, Medicine Development, Patient Advocacy, patient engagement, patient engagement in drug development, patient experience, Patient Recruitment, Patient Retention, Patients as Partners, Patients as Partners Europe, Peter DiBiaso, pharma, Pharmaceutical Conference, Regeneron, research and development, Roche, Royal National Hotel, Sanofi, Temi Olonisakin MD, The Conference Forum, Valerie Bowling
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative metastatic breast cancer patients. This new approval offers a potential treatment … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged breast cancer, DESTINY-Breast06 trial, diagnostic solutions, Enhertu, FDA, FDA approval, HER2-Low, HER2-targeted therapy, HER2-Ultralow, HR-positive, metastatic breast cancer, PATHWAY HER2, Personalized Treatment, Roche, treatment options
(IN BRIEF) Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for Duchenne muscular dystrophy (DMD). The results showed statistically significant and clinically meaningful improvements … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged 10-meter walk/run, 10MWR, clinical data, clinical efficacy, crossover group, delandistrogene moxeparvovec, disease-modifying treatment, Duchenne muscular dystrophy, Elevidys, EMBARK trial, external control group, functional improvements, gene therapy, micro-dystrophin, motor function, muscle biopsies, muscle function preservation, muscle pathology, North Star Ambulatory Assessment, NSAA, Phase III study, regulatory approvals, Roche, safety profile, Sarepta Therapeutics, Time to Rise, TTR
(IN BRIEF) Holcim has announced its next steps in preparing for the spin-off of its North American business, including the designation of the new Board of Directors. The 10-member Board will become official following shareholder and regulatory approvals, expected by … Read the full press release
Posted in Business, Construction, Industrial, Management, News, Switzerland, Technology
Tagged 3M Company, ABB, Alstom Group, appointment, BlueLinx Holdings Inc., CH2M HILL, Chairman, construction, Cristina A. Wilbur, Deloitte & Touche LLP, Delta Air Lines, Dwight Gibson, EG&G, F. Hoffmann-La Roche, Farmers Group, financial services, GEA Group AG, Genpact Limited, Gilbane Building Company, Governance, holcim, Holli Ladhani, Inc., independent directors, Industrial Operations, interface, Jan Jenisch, Jürg Oleas, Katja Roth Pellanda, leadership, Manufacturing, McDermott International, Michael E. McKelvy, Nicholas Gangestad, North American market, Novartis AG, Nucor Corporation, PerkinElmer Optoelectronics, Pritzker Private Capital, Quanta Services, regulatory approvals, Robert S. Rivkin, Roche, Rockwater Energy Solutions, Rockwell Automation, Select Energy Services, shareholder approvals, Sonoco Products Company, stakeholders, The Cato Corporation, Theresa Drew, United Airlines, Zurich Insurance, Zurich Italy Bank
(IN BRIEF) Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression narrowly missed statistical significance, promising efficacy trends were observed, … Read the full press release
(IN BRIEF) Roche has received CE certification for its enhanced cobas® 6800/8800 systems 2.0, introducing significant improvements in laboratory diagnostics. The upgrade streamlines operations by reducing downtime, consolidating test menus, and increasing throughput, supported by innovative TAGS technology that detects … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged cobas Systems 2.0, Matt Sause, Molecular Diagnostics, Roche, safety
(IN BRIEF) Roche’s Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). Serving over nine … Read the full press release
(IN BRIEF) Roche presented new data at the ASH 2024 meeting highlighting the effectiveness of its bispecific antibodies, Columvi and Lunsumio, in treating lymphomas. Long-term studies show durable remissions and immune system recovery with fixed-duration therapies, while real-world data emphasize … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged ASH 2024, Bispecific Antibodies, Columvi, Levi Garraway, Lunsumio, Lymphoma Treatment, Roche, safety
(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approximately $1 billion. Poseida stockholders may also receive up to $4.00 per share … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged acquisition, Aviv Regev, cell therapy, INNOVATION, Levi Garraway, partnership, Poseida Therapeutics, Roche, sustainability, USA
(IN BRIEF) Roche provided an update on its Phase III SKYSCRAPER-01 study, evaluating tiragolumab in combination with Tecentriq® for patients with PD-L1-high, advanced, or metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of improving … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Lung Cancer Therapy, Roche, safety, SKYSCRAPER-01 Study, TECENTRIQ, Tiragolumab
(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Dr. Komal Jhaveri, Healthcare, HR-Positive Breast Cancer, Itovebi, Levi Garraway, PIK3CA mutation, Roche, safety, Survival Benefits, wellness
(IN BRIEF) At the CTAD 2024 congress in Madrid, Roche presented new data on its Elecsys® Amyloid Plasma Panel and Elecsys ptau181, demonstrating their effectiveness in diagnosing Alzheimer’s disease. The blood-based test showed a negative predictive value of 96.2% in … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Spain, Switzerland, Technology
Tagged Alzheimer, Clinical Trials in Alzheimer’s Disease congress (CTAD) 2024, diagnostics, Elecsys ptau181, Elecsys® Amyloid Plasma Panel, Healthcare, Matt Sause, Roche, Spain
(IN BRIEF) The University of Liverpool has signed a Memorandum of Understanding (MoU) with Roche Diagnostics UK and Ireland to enhance research and innovation focused on improving health outcomes and addressing health inequalities. This partnership aims to align with Roche’s … Read the full press release
Posted in Business, Education, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged health innovation, Healthcare, inequalities, partnership, Professor Sarah Coupland, Professor Tim Jones, Roche, sustainability, University of Liverpool, wellness
(IN BRIEF) Roche has announced positive two-year data from its RAINBOWFISH study, showcasing the effectiveness of Evrysdi® (risdiplam) in treating children with spinal muscular atrophy (SMA) when administered before symptoms appear. The study revealed that most children achieved key motor … Read the full press release
(IN BRIEF) Roche has announced the CE certification of its VENTANA CLDN18 (43-14A) RxDx Assay, marking a significant advancement in companion diagnostics for patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. This diagnostic tool enables clinicians to identify patients who … Read the full press release
(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active lupus nephritis. The study found that patients receiving Gazyva/Gazyvaro, in combination with standard therapies, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Dr. Brad H. Rovin, Gazyva, kidney disease patients, Levi Garraway, lupus nephritis, Roche, safety
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?